Medical Innovation Ventures Sdn. Bhd. (Mediven) has announced a groundbreaking collaboration with AstraZeneca Malaysia, a global biopharmaceutical powerhouse. This partnership aims to revolutionise healthcare in Malaysia by focusing on the diagnosis and awareness of prostate cancer. 

The collaboration between seeks to engage hospitals, doctors, and specialists while simultaneously raising awareness about screening of prostate cancer. Both companies are committed to providing free PSA screenings for patients in various hospitals as part of their joint initiative.

As part of this collaboration, Mediven will contribute its state-of-the-art diagnostic kit, The Finecare PSA Rapid Quantitative Test. This test, a fluorescence immunoassay, is designed to work seamlessly with the Finecare FIA System for the quantitative determination of Prostate Specific Antigen (PSA) in human whole blood, serum, or plasma. The Finecare PSA Rapid Quantitative Test serves as a crucial aid in the diagnosis of prostatic cancer.

Prostate cancer is a significant health concern globally, and this collaboration aims to make a meaningful impact on early detection and proactive management. By offering free screenings in hospitals, MEDIVEN and AstraZeneca Malaysia aim to identify potential cases early on, allowing for timely intervention and improved patient outcomes.

"MyDocLab, the partner digital app of Mediven, will also support this noble initiative by informing the public on the free screening schedule and education material on our website," said Dr Lim Li Sze, Operations Director at Mediven.